TLDR
- Eli Lilly (LLY) has acquired preclinical biotech Engage Biologics for up to $202M in cash.
- Engage Bio has developed the Tethosome platform, a non-viral DNA delivery system using lipid nanoparticle and mRNA technology.
- The deal includes an upfront payment plus additional milestone-based payments.
- The acquisition is aimed at advancing a new class of genetic medicines and overcoming issues with existing DNA delivery methods.
- This is part of a broader acquisition push by Lilly in 2025–2026, which also includes Ajax, Kelonia, Centessa, and Orna Therapeutics.
Eli Lilly has made another move in genetic medicine, snapping up Engage Biologics for up to $202 million. LLY stock was trading around $823 at the time of the announcement.
Founded in 2021, Engage Bio is a San Carlos, California-based startup that has been working on a non-viral DNA delivery system called the Tethosome platform. The company has not yet reached the clinical stage.
The Tethosome platform is designed to deliver DNA payloads to human tissue. It combines lipid nanoparticle and mRNA technology to do so.
The focus is on solving real problems with current DNA delivery methods — specifically issues around potency, tolerability, and the ability to re-dose patients over time.
The $202M price tag includes an upfront payment to Engage, with additional payments tied to hitting specific development milestones.
A Growing Bet on Genetic Medicine
This deal fits neatly into a pattern. Lilly has been on an acquisition spree, picking up companies across the genetic medicine landscape throughout the past year or so.
Other recent deals include Ajax Therapeutics, Kelonia Therapeutics, Centessa Pharmaceuticals, and Orna Therapeutics — several of which were multibillion-dollar transactions.
Engage Bio CEO Will Olsen framed the deal positively. “We are excited to begin our next chapter with Lilly, which has demonstrated unmatched speed and a uniquely forward-thinking approach to genetic medicine,” he said.
Olsen added that the combination of Engage’s platform and Lilly’s capabilities should speed up development of new genetic therapies.
Despite being founded just four years ago and operating with lean resources, Engage Bio managed to build a technology platform that caught Lilly’s attention.
“With a lean organization and modest seed funding, I am incredibly proud of the rapid progress Engage has made toward a new class of genetic medicines,” Olsen said.
What Lilly Gets From the Deal
Non-viral delivery systems are increasingly seen as a promising direction in gene therapy. Traditional viral vectors come with limitations around immune response and manufacturing.
Lipid nanoparticles, the same technology used in mRNA COVID-19 vaccines, have become a key tool for delivering genetic cargo into cells.
The Tethosome platform builds on that foundation, with the aim of delivering DNA — rather than just RNA — more reliably to target tissues.
For Lilly, adding this kind of early-stage platform technology gives it more options as it builds out its genetic medicine pipeline.
Engage Bio had not yet entered human trials, meaning Lilly is buying potential rather than proven results. Milestone payments help structure the risk accordingly.
The acquisition was announced on Wednesday, May 20, 2026.
🚨 Our MAY Stock Picks Are Live!
A new month means new opportunities. Our analysts have just released their top stock picks for May, highlighting companies with strong momentum that rank highly on our KO Score algorithm. We’re also now sharing trade ideas for both long-term and short-term investors, giving you more ways to spot potential opportunities in the market.
Sign up to Knockout Stocks today and get 50% off to unlock the full list and see which stocks made the cut.
Use coupon code Special50 for your exclusive discount!
Be the first to comment